FDA gives nod to BioMarin’s Ireland bulk biologic manufacturing facility

The Ireland-based plant is the first international manufacturing facility for BioMarin.

The FDA approved manufacturing operations at BioMarin’s Cork, Ireland, bulk biologic manufacturing facility that will produce an ingredient of Vimizim used to treat Morquio syndrome.

The plant is the first international manufacturing facility for BioMarin, which bought the operations from Pfizer in 2011.

The company has said it plans to expand the facility from its current 200,000 square feet situated on 20 acres to include an expanded warehouse, utilities and new office space, the Irish Examiner reported.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The site received EMA approval earlier this year.

"The Shanbally plant greatly expands our manufacturing capacity to accommodate our growing commercial portfolio and advancing clinical programs, as well as diversifies manufacturing risk associated by now having two licensed facilities,” said Jean-Jacques Bienaimé, BioMarin’s chairman and CEO. “In addition, it provides flexibility and capacity for our largest and fastest growing commercial product, Vimizim, to meet projected demand for the foreseeable future. The flexible state-of-the-art facility gives us tremendous latitude for the types of products that can be produced at the facility."

The company said with the regulatory agency approval it will shift the focus of its manufacturing of Vimizim to Ireland.

Suggested Articles

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

What challenges continue to plague the pharmaceutical industry for almost a decade? Check out this remarkable innovation in glass science that may be the…

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.